Zynerba (NASDAQ: ZYNE) is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and 22q11.2 deletion syndrome.
Zygel is a unique permeation-enhanced cannabidiol transdermal gel. Transdermal therapeutics are applied topically and absorbed through the skin directly into the systemic circulation, resulting in a lower incidence of gastrointestinal side effects, and avoidance of first-pass liver metabolism, which potentially enables lower dosage levels of active pharmaceutical ingredients and rapid, reliable absorption with increased bioavailability. Other potential benefits of transdermal delivery compared with oral administration may include fewer drug-drug interactions.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™ (formerly known as ZYN002):
Zygel is the first and only pharmaceutically-manufactured cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-manufactured cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. Zygel is being developed for patients affected by Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). Zygel is an investigational treatment. This means that it is not yet approved for commercial distribution by government regulatory bodies, including the U.S. Food and Drug Administration (FDA).
Cannabinoids appear to modulate a number of systems, channels and receptors; as such, they may have the potential to be developed in a number of additional important indications, including anxiety, autism spectrum disorder, neuroprotection, cognitive disorders, sleep disturbance, and treatment for certain neuralgias.
At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare neuropsychiatric conditions. Often, these conditions have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patients and their families as they battle these conditions.
Our goal is to advance the science of therapeutic cannabinoids, and to improve the lives of patients battling severe neuropsychiatric conditions including FXS and 22q.
Our approach is to utilize our pharmaceutically-manufactured, permeation-enhanced, transdermal gel to modulate pathways in the central nervous system that, when disrupted, cause certain neurological conditions. By doing so, we hope to provide new treatment options for patients battling certain orphan neuropsychiatric conditions.